JP2016506398A - そう痒の処置法 - Google Patents

そう痒の処置法 Download PDF

Info

Publication number
JP2016506398A
JP2016506398A JP2015548006A JP2015548006A JP2016506398A JP 2016506398 A JP2016506398 A JP 2016506398A JP 2015548006 A JP2015548006 A JP 2015548006A JP 2015548006 A JP2015548006 A JP 2015548006A JP 2016506398 A JP2016506398 A JP 2016506398A
Authority
JP
Japan
Prior art keywords
per day
nalbuphine
sustained release
dose
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015548006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016506398A5 (enExample
Inventor
トーマス シャーシャ
トーマス シャーシャ
Original Assignee
トレビ セラピューティクス インコーポレイテッド
トレビ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/715,625 external-priority patent/US8637538B1/en
Application filed by トレビ セラピューティクス インコーポレイテッド, トレビ セラピューティクス インコーポレイテッド filed Critical トレビ セラピューティクス インコーポレイテッド
Publication of JP2016506398A publication Critical patent/JP2016506398A/ja
Publication of JP2016506398A5 publication Critical patent/JP2016506398A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
JP2015548006A 2012-12-14 2013-12-13 そう痒の処置法 Pending JP2016506398A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261737488P 2012-12-14 2012-12-14
US13/715,625 2012-12-14
US61/737,488 2012-12-14
US13/715,625 US8637538B1 (en) 2012-12-14 2012-12-14 Methods for treatment of pruritis
PCT/US2013/075096 WO2014093871A1 (en) 2012-12-14 2013-12-13 Methods for treating pruritus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019071738A Division JP6823857B2 (ja) 2012-12-14 2019-04-04 抗そう痒剤

Publications (2)

Publication Number Publication Date
JP2016506398A true JP2016506398A (ja) 2016-03-03
JP2016506398A5 JP2016506398A5 (enExample) 2017-01-26

Family

ID=50935003

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015548006A Pending JP2016506398A (ja) 2012-12-14 2013-12-13 そう痒の処置法
JP2019071738A Active JP6823857B2 (ja) 2012-12-14 2019-04-04 抗そう痒剤
JP2020179395A Active JP7072280B2 (ja) 2012-12-14 2020-10-27 抗そう痒剤
JP2022072885A Pending JP2022105095A (ja) 2012-12-14 2022-04-27 抗そう痒剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019071738A Active JP6823857B2 (ja) 2012-12-14 2019-04-04 抗そう痒剤
JP2020179395A Active JP7072280B2 (ja) 2012-12-14 2020-10-27 抗そう痒剤
JP2022072885A Pending JP2022105095A (ja) 2012-12-14 2022-04-27 抗そう痒剤

Country Status (13)

Country Link
EP (1) EP2931279B1 (enExample)
JP (4) JP2016506398A (enExample)
KR (3) KR20150093702A (enExample)
CN (2) CN110585209A (enExample)
AU (2) AU2013359017B2 (enExample)
BR (1) BR112015013984A2 (enExample)
CA (1) CA2892393C (enExample)
ES (1) ES2984559T3 (enExample)
MX (1) MX2015007518A (enExample)
NZ (1) NZ708371A (enExample)
RU (1) RU2015128265A (enExample)
WO (1) WO2014093871A1 (enExample)
ZA (2) ZA201504229B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017517553A (ja) * 2014-06-13 2017-06-29 トレビ セラピューティクス インコーポレイテッド 掻痒の治療方法
JP2019532112A (ja) * 2016-10-25 2019-11-07 トレビ セラピューティクス インコーポレイテッド 結節性痒疹の治療方法
JP2021531299A (ja) * 2018-07-23 2021-11-18 トレビ セラピューティクス インコーポレイテッド 慢性咳嗽、息切れ、及び呼吸困難の治療
JP2023184779A (ja) * 2017-02-03 2023-12-28 株式会社東洋新薬 固形製剤
US12274696B2 (en) 2020-01-10 2025-04-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
JP2016506398A (ja) * 2012-12-14 2016-03-03 トレビ セラピューティクス インコーポレイテッド そう痒の処置法
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
CA2988289C (en) 2015-06-04 2023-12-05 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
TW201725041A (zh) * 2016-01-04 2017-07-16 懷特生技新藥股份有限公司 治療皮膚癢之醫藥組合物
CN105560202B (zh) * 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用
EP3432871B1 (en) * 2016-03-21 2023-11-15 Trevi Therapeutics, Inc. Treatment of uremic pruritus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502603A (ja) * 2004-06-03 2008-01-31 バーボーム，ジョナサン，ジェイ． そう痒症を処置するための医薬組成物
JP2009506059A (ja) * 2005-08-24 2009-02-12 ペンウエスト ファーマシューティカルズ カンパニー ナルブフィンの徐放性製剤
WO2012022919A2 (fr) * 2010-08-20 2012-02-23 Debregeas Et Associes Pharma Formulations à base de nalbuphine et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2285733T3 (es) * 1996-11-25 2007-11-16 Toray Industries, Inc. Agente antipruritico.
US20030054030A1 (en) * 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
US6703398B2 (en) * 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
DK2425821T5 (en) * 2002-04-05 2018-02-12 Mundipharma As Pharmaceutical preparation containing oxycodone and naloxone
US8394812B2 (en) * 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
JP2016506398A (ja) * 2012-12-14 2016-03-03 トレビ セラピューティクス インコーポレイテッド そう痒の処置法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502603A (ja) * 2004-06-03 2008-01-31 バーボーム，ジョナサン，ジェイ． そう痒症を処置するための医薬組成物
JP2009506059A (ja) * 2005-08-24 2009-02-12 ペンウエスト ファーマシューティカルズ カンパニー ナルブフィンの徐放性製剤
WO2012022919A2 (fr) * 2010-08-20 2012-02-23 Debregeas Et Associes Pharma Formulations à base de nalbuphine et leurs utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHANG GUNG MEDICAL JOURNAL, vol. 34, no. 2, JPN6017031509, 2011, pages 172 - 178, ISSN: 0003815656 *
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, vol. 25, no. 3, JPN6017031511, 1999, pages 209 - 213, ISSN: 0003815657 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017517553A (ja) * 2014-06-13 2017-06-29 トレビ セラピューティクス インコーポレイテッド 掻痒の治療方法
JP2019532112A (ja) * 2016-10-25 2019-11-07 トレビ セラピューティクス インコーポレイテッド 結節性痒疹の治療方法
JP2022191405A (ja) * 2016-10-25 2022-12-27 トレビ セラピューティクス インコーポレイテッド 結節性痒疹を治療するための抗掻痒剤
JP2023184779A (ja) * 2017-02-03 2023-12-28 株式会社東洋新薬 固形製剤
JP2023184766A (ja) * 2017-02-03 2023-12-28 株式会社東洋新薬 錠剤及び錠剤の製造方法
JP7745283B2 (ja) 2017-02-03 2025-09-29 株式会社東洋新薬 錠剤及び錠剤の製造方法
JP2021531299A (ja) * 2018-07-23 2021-11-18 トレビ セラピューティクス インコーポレイテッド 慢性咳嗽、息切れ、及び呼吸困難の治療
US11660296B2 (en) 2018-07-23 2023-05-30 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
JP2024153828A (ja) * 2018-07-23 2024-10-29 トレビ セラピューティクス インコーポレイテッド 慢性咳嗽、息切れ、及び呼吸困難の治療
US12274696B2 (en) 2020-01-10 2025-04-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine

Also Published As

Publication number Publication date
JP7072280B2 (ja) 2022-05-20
ZA201504229B (en) 2021-07-28
EP2931279A4 (en) 2016-05-11
WO2014093871A1 (en) 2014-06-19
CN110585209A (zh) 2019-12-20
JP2019131588A (ja) 2019-08-08
KR20150093702A (ko) 2015-08-18
ZA201906339B (en) 2021-07-28
AU2018214098B2 (en) 2019-04-18
KR20220044385A (ko) 2022-04-07
NZ708371A (en) 2020-05-29
AU2013359017B2 (en) 2018-05-10
AU2018214098A1 (en) 2018-08-30
HK1215541A1 (en) 2016-09-02
JP6823857B2 (ja) 2021-02-03
EP2931279A1 (en) 2015-10-21
RU2015128265A (ru) 2017-01-25
CA2892393C (en) 2021-06-08
KR20210050585A (ko) 2021-05-07
CA2892393A1 (en) 2014-06-19
EP2931279B1 (en) 2024-03-20
JP2022105095A (ja) 2022-07-12
BR112015013984A2 (pt) 2017-07-11
ES2984559T3 (es) 2024-10-29
AU2013359017A1 (en) 2015-06-11
JP2021020947A (ja) 2021-02-18
CN104981246A (zh) 2015-10-14
MX2015007518A (es) 2016-03-01

Similar Documents

Publication Publication Date Title
JP7072280B2 (ja) 抗そう痒剤
US20250032480A1 (en) Methods for treating pruritus
US8987289B2 (en) Methods for treating pruritus
US20190099416A1 (en) Methods for treating pruritus
US8637538B1 (en) Methods for treatment of pruritis
US20170216277A1 (en) Therapeutic use of nalbuphine without aquaretic effects
EP3432871B1 (en) Treatment of uremic pruritus
HK40013011A (en) Methods for treating pruritus
HK1215541B (en) Methods for treating pruritus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181205